Gilead Sciences Just Received Orphan Drug Status For Liver Treatment
The designation, which concerns its potential as a treatment for primary sclerosing cholangitis, may provide Gilead increased patent protection and lower regulatory hurdles.
The status is reserved for treatments of diseases that affect fewer than 200,000 people in the United States, or for drugs that aren't expected to recover development costs.
Liver transplant is the only current treatment for primary sclerosing cholangitis.
Gilead is also attempting to develop simtuzamab as a treatment for liver Fibrosis and nonalcoholic steatohepatitis.
Simtuzamab in September proved unsuccessful in a Phase II trial as a treatment for pancreatic cancer.
Shares of Gilead Sciences changed hands recently at $98.73, up 1.1 percent.
Image credit: Jeffrey Beall, Wikimedia
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.